2025-07-28 - Analysis Report
Okay, here's a comprehensive analysis of Teladoc Health Inc. (TDOC), incorporating all the provided data points:

**Report on Teladoc Health Inc. (TDOC)**

Teladoc Health Inc. provides virtual healthcare services, connecting patients with doctors remotely.

**1. Performance Analysis vs. S&P 500 (VOO)**

*   **Cumulative Return:**
    *   TDOC: -64.52%
    *   VOO: 100.74%
*   **Relative Performance (Spread):**
    *   Current Spread: -164.5
    *   Max Spread: 456.6
    *   Min Spread: -164.5
    *   Relative Spread Position: 0.0

**Analysis:** TDOC has significantly underperformed the S&P 500 (VOO). The current spread of -164.5 indicates substantial negative deviation. The relative spread position of 0.0 suggests that the underperformance is at its worst level within the observed data range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| :----------- | :------ | :---- | :------ | :---- | :------- |
| 2015-2017  | 76.0%  | 60.6% | 50.0%  | -0.0 | 6.1    |
| 2016-2018  | 128.0% | 59.3% | 110.0% | -0.0 | 8.7    |
| 2017-2019  | 176.0% | 59.3% | 147.0% | 0.4  | 14.7   |
| 2018-2020  | 237.0% | 64.0% | 217.0% | 0.1  | 35.1   |
| 2019-2021  | -83.0%  | 64.0% | -132.0% | 0.1  | 16.1   |
| 2020-2022  | -295.0% | 81.3% | -297.0% | 0.0  | 4.2    |
| 2021-2023  | -488.0% | 81.3% | -506.0% | -0.6 | 3.8    |
| 2022-2024  | -111.0% | 81.3% | -137.0% | -0.8 | 1.6    |
| 2023-2025  | -35.0%  | 72.9% | -87.0%  | -0.8 | 1.4    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows very high growth in earlier periods, followed by significant negative growth in recent years. This indicates a major shift in the company's performance.
*   **MDD:**  Maximum Drawdown is consistently high, suggesting significant volatility and risk.
*   **Alpha:**  Alpha values were high in earlier periods but have become strongly negative, signifying underperformance relative to the market.
*   **Beta:**  Beta values are generally low, indicating that the stock has not been strongly correlated with the market. In recent years, Beta has become negative, implying an inverse relationship with the market.
*   **Cap(B):**  The market capitalization has significantly decreased in recent years, reflecting the stock's poor performance.

**2. Recent Stock Price Movement**

*   **Current Price:** $8.20
*   **Previous Close:** $8.20
*   **Change:** $0.00
*   **5-day Moving Average:** 8.346
*   **20-day Moving Average:** 8.3375
*   **60-day Moving Average:** 7.5725

**Analysis:** The stock price is essentially flat, with very little change.  The 5-day and 20-day moving averages are very close, indicating a lack of strong short-term trend. The 60-day moving average is lower, suggesting the price is still recovering from a downtrend over the past couple of months.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 52.2968
*   **PPO:** -0.5359
*   **Hybrid Signal:** cash_69%_Sell 1.0% of holdings (16 shares - Caution - MRI:0.33) (Cash Ratio: 69% on 2025-07-23)
*   **Recent (20-day) Relative Spread Change:** 0.0 (Negative Trend)
*   **Expected Return (%):** -9774.4%

**Analysis:**

*   The MRI is in the low-risk range, indicating relatively stable market conditions for the stock.
*   RSI is at 52.30, indicating a neutral level – neither overbought nor oversold.
*   PPO is slightly negative (-0.54), suggesting a mild downward trend, but not significant.
*   Hybrid Signal is "Sell 1.0%", indicating a cautious stance, suggesting to reduce holdings slightly.
*   The Expected Return is extremely negative, indicating a very pessimistic outlook for long-term investment in TDOC compared to the S&P 500.
*   The "price": 8.2, "previousClose": 8.2, "change": 0.0 is a no event

**4. Recent News & Significant Events**

*   **[2025-07-24]:** Major business developments, regulatory changes, or market events impacting TDOC.
*   **[2025-07-28]:** Analysts discussing TDOC's performance and outlook considering industry trends and global economic factors.
*   **[2025-07-26]:** TDOC's stock showing notable volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-27]:** Market experts highlighting both risks and opportunities for TDOC.

**Analysis:**  Recent news indicates that TDOC is facing significant changes and volatility. Analyst discussions and market expert opinions highlight both risks and potential opportunities.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출       |
| :--------- | :----- | :--------- |
| 2025-05-01 | -0.53  | 0.63 B$    |
| 2024-10-31 | -0.19  | 0.64 B$    |
| 2024-08-01 | -4.92  | 0.64 B$    |
| 2024-04-26 | -0.49  | 0.65 B$    |
| 2025-05-01 | -0.49  | 0.65 B$    |

**Analysis:**  Teladoc Health has consistently reported negative Earnings Per Share (EPS) over the past several quarters. Revenue has been relatively stable around $0.64 billion, with a slight decrease in the most recent quarter. The significant loss in Q3 2024 (EPS of -4.92) is particularly concerning.

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :------------ |
| 2025-03-31 | $0.63B  | 68.73%      |
| 2024-12-31 | $0.64B  | 70.50%      |
| 2024-09-30 | $0.64B  | 71.94%      |
| 2024-06-30 | $0.64B  | 70.73%      |
| 2024-03-31 | $0.65B  | 69.89%      |

Capital and Profitability:

| Quarter      | Equity    | ROE     |
| :----------- | :-------- | :------ |
| 2025-03-31 | $1.43B  | -6.52% |
| 2024-12-31 | $1.49B  | -3.25% |
| 2024-09-30 | $1.51B  | -2.21% |
| 2024-06-30 | $1.50B  | -55.77% |
| 2024-03-31 | $2.29B  | -3.58% |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been relatively stable, but the most recent quarter shows a slight decline.  Gross profit margins are high, consistently above 68%, indicating a good ability to control the cost of goods sold.
*   **Capital and Profitability:** Equity has been decreasing, indicating a decline in the company's net worth.  ROE is negative for all periods, reflecting the company's inability to generate profits from its equity. The significantly negative ROE in Q2 2024 (-55.77%) is a major red flag.

**7. Overall Analysis and Summary**

Teladoc Health Inc. (TDOC) faces significant challenges. The stock has drastically underperformed the S&P 500, with a large negative spread and a current relative spread position at its lowest point. While the Market Risk Indicator (MRI) shows low risk, the recent news indicates potential volatility and significant changes. The EPS has been negative for multiple quarters, and although revenue is relatively stable, profitability is weak, as reflected by the negative ROE and the large losses in certain quarters. The extremely negative expected return suggests substantial long-term concerns. The analysis shows a company with high volatility and risk.

**In conclusion, based on the provided data, Teladoc Health Inc. (TDOC) appears to be a high-risk investment.** While there may be potential opportunities as highlighted by market experts, the current financial metrics, recent performance, and negative outlook warrant caution.
